Table 1.
Effect of oral administration of different doses of FIIc on fasting blood glucose (mg/dl) at various time intervals
Group | Dose | Day 0 | Day 6 | Day 10 | Day 20 | Day 30 |
---|---|---|---|---|---|---|
Healthy control | — | 83.10 ± 4.5 | 79.50 ± 10.2 | 84.90 ± 5.0 | 83.70 ± 7.6 | 83.50 ± 8.0 |
Diabetic control | — | 301.5 ± 17.1 | 306.3 ± 12.9 | 313.7 ± 13.9a | 322.4 ± 10.3a | 326.3 ± 9.8a |
Diabetic + Glibenclamide | 600 μg | 302.9 ± 16.4 | 259.5 ± 39.5a | 208.3 ± 21.9a | 187.1 ± 23.2a | 144.1 ± 17.9a |
Diabetic + FIIc | 10 mg | 302.6 ± 13.1 | 300.9 ± 19.6 | 276.0 ± 25.4a | 213.3 ± 28.3a | 187.8 ± 16.8a |
Diabetic + FIIc | 15 mg | 306.5 ± 14.9 | 269.0 ± 31.2a | 228.5 ± 26.7a | 155.1 ± 27.4a | 121.2 ± 16.8a |
Diabetic + FIIc | 20 mg | 301.8 ± 12.1 | 298.1 ± 27.3 | 259.8 ± 26.2a | 195.4 ± 30.2a | 132.3 ± 18.6a |
Data are expressed as mean ± SEM of five animals in each group and evaluated by repeated measure ANOVA followed by Dunnett's test.
a P < .001 versus day 0.